title: Statins in the prevention of cardiovascular events in patients with renal failure.
abstract: HMG-CoA reductase inhibitors (statins) are among the most widely used hypolypemizing drugs with a pleiotropic activity. Numerous clinical trials have demonstrated that statins can have a significant effect in the prevention of cardiovascular diseases in the general population. In patients with renal failure, this drug preserves the hypolypemizing efficacy found in the general population without increasing their unwanted side-effects. The re-analysis of data from epidemiological studies conducted on the general population has confirmed that statins provide cardiovascular protection also in subjects with renal failure. These data have been partly confirmed by the findings made by 4D (Die Deutsche Diabetes Dialyse Studie) and Alert studies, conducted on diabetic patients on dialysis and patients with renal transplants, respectively. The results of other studies, such as AURORA, SHARP, REnal and Vascular End stage Disease, and ESPLANADE, clearly indicate that statins prevent cardiovascular disease in patients with renal insufficiency, just as they do in the general population.
authors.affiliation: Cattedra di Nefrologia, Dipartimento di Medicina Interna, Università di Messina, Via Salita Villa Contino, 98100 Messina, Italy. buemim@unime.it
authors.forename: Michele
authors.initials: M
authors.lastname: Buemi
authors.forename: Fulvio
authors.initials: F
authors.lastname: Floccari
authors.forename: Lorena
authors.initials: L
authors.lastname: Nostro
authors.forename: Susanna
authors.initials: S
authors.lastname: Campo
authors.forename: Chiara
authors.initials: C
authors.lastname: Caccamo
authors.forename: Alessio
authors.initials: A
authors.lastname: Sturiale
authors.forename: Carmela
authors.initials: C
authors.lastname: Aloisi
authors.forename: Maria Stella
authors.initials: MS
authors.lastname: Giacobbe
authors.forename: Nicola
authors.initials: N
authors.lastname: Frisina
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000503:physiopathology; D016030:Kidney Transplantation; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications* / Q000503:physiopathology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors